|
Video: What is a Stock Split?
|
|
Spero Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments involving bacterial infections. Co.'s product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial pulmonary disease. Co.'s partnership-directed programs consist of tebipenem pivoxil hydrobromide, which is designed to be oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections; and SPR206, which is an IV-administered antibiotic being developed as an option to treat multi-drug resistant Gram-negative bacterial infections in the hospital setting. According to our SPRO split history records, Spero Therapeutics has had 0 splits. | |
|
Spero Therapeutics (SPRO) has 0 splits in our SPRO split history database.
Looking at the SPRO split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Spero Therapeutics shares, starting with a $10,000 purchase of SPRO, presented on a split-history-adjusted basis factoring in the complete SPRO split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/02/2017 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$11.50 |
|
End price/share: |
$1.75 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-84.78% |
|
Average Annual Total Return: |
-25.48% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,521.23 |
|
Years: |
6.40 |
|
|
|
|
|